Keryx Biopharmaceuticals Inc fka KERX

[califax]

Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations

Date : 06/03/2010 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)

http://ih.advfn.com/p.php?pid=nmona&article=43080377&symbol=N^KERX

PR Newswire

NEW YORK, June 3

NEW YORK, June 3 /PRNewswire-FirstCall/ --

Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the following June Investor conferences:

Wednesday, June 9, 2010 – 1:20 p.m. EDT

9th Annual Needham Healthcare Conference

New York Palace Hotel

New York City

Thursday, June 10, 2010 – 9:00 a.m. EDT

Jefferies Global Life Sciences Conference

New York City

A live audio webcast of Mr. Bentsur's presentations will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: [phone]

E-mail: [e-mail]

SOURCE Keryx Biopharmaceuticals, Inc.